	US 11,680,102 B2
	Anti-BAFF receptor antibodies and uses thereof
Jianbing Zhang, Guangdong (CN); Hong Qin, Upland, CA (US); and Larry W. Kwak, Pasadena, CA (US)
Assigned to Yinnuolai Biotech Ltd., Guangzhou (CN); and City of Hope, Duarte, CA (US)
Filed by YINNUOLAI BIOTECH LTD., Guangdong (CN); and CITY OF HOPE, Duarte, CA (US)
Filed on Feb. 19, 2021, as Appl. No. 17/179,467.
Prior Publication US 2021/0261676 A1, Aug. 26, 2021
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2878 (2013.01) [C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/92 (2013.01)]

11 Claims

1. An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequence of:

a. SEQ ID NOs:3, 4, 5, 6, 7, and 8, respectively;

wherein the antibody or antigen-binding fragment thereof specifically binds B-cell activating factor (BAFF) receptor.